SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.36+3.4%10:31 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (16773)5/13/2005 5:44:24 PM
From: former_pgs  Read Replies (1) of 52153
 
Perhaps telik has been cherry picking for a while now? ;-)

They have reproducibly shown good synergy in the clinic with the platinum compounds. The presentation on tuesday with telcyta + cisplatin in NSCLC will hopefully show similar synergy, as that trial has been open for an additional 6-8 months longer than today's triplet trial which treated its first patient in august.

Couple of notes from the conference call:

Wick was suggesting that some of the PRs in this trial were pushing 90% or above reduction in tumour size. They may look at 2 doses of Telcyta in the phase II portion of this trial which is currently ongoing.

Their ASSIST-2 phase III trial testing Telcyta vs Iressa has completed enrollment.

Their strategy for presenting the results from the randomized ASSIST-1, 2 and 3 trials will be to put out an announcement of when the last "event" occurs to trigger the analysis, and then present data 12-16 weeks following this event.

For ASSIST-1, they noted that they're not even halfway to the number of events required to trigger the analysis. This is a 440 patient trial in refractory ovarian cancer. It sounds pretty clear to me that they will not have the data for these trials in calendar year 2005.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News